Royal Biologics to invest in Coldplasmatech.

Royal Biologics, an orthobiologics and life science company, agreed to invest in Coldplasmatech, a provider of medical cold plasma technology. Financial terms were not disclosed. "Our partnership with Royal Biologics marks a critical milestone. Chronic wounds remain a global healthcare burden, and our CPT® cold plasma therapy offers a transformative solution-combating multi-drug-resistant bacteria, and significantly improving patient outcomes," Dr. Carsten Mahrenholz, Coldplasmatech CEO.